MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

Search

Certara Inc

Slēgts

SektorsVeselības aprūpe

9.37 0.11

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

9.09

Max

9.41

Galvenie mērījumi

By Trading Economics

Ienākumi

3.5M

1.5M

Pārdošana

46K

105M

P/E

Sektora vidējais

129.143

87.826

Peļņas marža

1.458

Darbinieki

1,487

EBITDA

-6.5M

23M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+25.23% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 25. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-439M

1.4B

Iepriekšējā atvēršanas cena

9.26

Iepriekšējā slēgšanas cena

9.37

Ziņu noskaņojums

By Acuity

50%

50%

158 / 370 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Certara Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 12. janv. 23:54 UTC

Tirgus saruna

CBA Could Underperform Again in 2026 -- Market Talk

2026. g. 12. janv. 23:48 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 12. janv. 23:48 UTC

Tirgus saruna

Nikkei May Rise on Weaker Yen -- Market Talk

2026. g. 12. janv. 23:43 UTC

Tirgus saruna

Gold Edges Lower on Likely Technical Correction -- Market Talk

2026. g. 12. janv. 23:18 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

2026. g. 12. janv. 21:56 UTC

Tirgus saruna

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

2026. g. 12. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 12. janv. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 12. janv. 21:50 UTC

Tirgus saruna
Peļņas

Auto & Transport Roundup: Market Talk

2026. g. 12. janv. 21:18 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 12. janv. 21:18 UTC

Tirgus saruna

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

2026. g. 12. janv. 20:54 UTC

Peļņas

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

2026. g. 12. janv. 20:48 UTC

Tirgus saruna

Oil Futures Settle Higher in Choppy Trade -- Market Talk

2026. g. 12. janv. 20:33 UTC

Tirgus saruna

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

2026. g. 12. janv. 20:18 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

2026. g. 12. janv. 20:18 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

2026. g. 12. janv. 19:39 UTC

Tirgus saruna

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

2026. g. 12. janv. 19:36 UTC

Tirgus saruna

Gold and Silver Set New Records on Fed Probe -- Market Talk

2026. g. 12. janv. 19:36 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 12. janv. 19:33 UTC

Tirgus saruna

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

2026. g. 12. janv. 19:24 UTC

Iegādes, apvienošanās, pārņemšana

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

2026. g. 12. janv. 19:22 UTC

Iegādes, apvienošanās, pārņemšana

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

2026. g. 12. janv. 18:21 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

2026. g. 12. janv. 18:20 UTC

Iegādes, apvienošanās, pārņemšana

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

2026. g. 12. janv. 18:19 UTC

Tirgus saruna

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

2026. g. 12. janv. 18:16 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

2026. g. 12. janv. 18:09 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 12. janv. 18:09 UTC

Tirgus saruna

Baidu's Outlook Bodes Well For Shares -- Market Talk

2026. g. 12. janv. 18:01 UTC

Iegādes, apvienošanās, pārņemšana

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

2026. g. 12. janv. 18:00 UTC

Tirgus saruna

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Salīdzinājums

Cenas izmaiņa

Certara Inc Prognoze

Cenas mērķis

By TipRanks

25.23% augšup

Prognoze 12 mēnešiem

Vidējais 12.11 USD  25.23%

Augstākais 16 USD

Zemākais 9 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Certara Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

7

Pirkt

4

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

11.27 / 12.79Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Very Strong Bullish Evidence

Ilgtermiņā

Strong Bullish Evidence

Noskaņojums

By Acuity

158 / 370 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat